 |
|
Children's Hospital scientists identify possible target for prevention and treatment of pneumonia
February 12, 2008Results of first-of-its-kind research published in the Feb. 10 online edition of Nature Medicine
Researchers at Children's Hospital of Pittsburgh of UPMC have identified a key protein target that may be a crucial factor in the development of a vaccine to prevent and new therapies to treat pneumonia, the leading killer of children worldwide.
Research led by Jay K. Kolls, MD, chief of the Division of Pediatric Pulmonary Medicine, Allergy and Immunology at Children's, identified for the first time the importance of a protein known as interleukin 22 (IL-22) in the immune response to a strain of bacterial pneumonia. In the laboratory, the researchers were able to effectively treat mice with pneumonia by using purified IL-22.
Results of the study are published in the February online issue of Nature Medicine.
"Currently there is no vaccine that covers all kinds of pneumonia and antibiotic treatment is sometimes limited by antibiotic resistance. As acute respiratory infections are the no. 1 killer of children in the world, progress in the development of novel vaccines or new, more effective treatments is critical," said Dr. Kolls, the Neils K. Jerne Professor of Pediatrics and Immunology at the University of Pittsburgh School of Medicine. "Our results raise the possibility of developing new protein-based therapies using IL-22 to limit or prevent pneumonia."
Pneumonia causes almost one in five deaths in children under age 5 worldwide - more than 2 million children each year, according to the World Health Organization. It kills more children than any other disease - more than AIDS and malaria combined.
IL-22 and interleukin 17A (IL-17A) are produced by a recently discovered lineage of cells known as T Helper Type 17 (Th17). Children's researchers found evidence that the Th17 cell lineage and its cytokines IL-22 and IL-17A have evolved to promote host defense against certain infections in the lung caused by extracellular pathogens.
This is an important discovery because the Children's research team proposes that by stimulating the Th17 arm of the immune system, they can more efficiently treat bacterial pneumonia. Furthermore, the researchers propose that Th17 is a less critical pathway for intracellular bacteria such as those that cause listeria and tuberculosis - thus raising the potential to target this pathway in diseases of chronic inflammation such as rheumatoid arthritis or inflammatory bowel disease without increasing susceptibility to these intracellaulr pathogens.
Dr. Kolls' laboratory investigates mechanisms of lung host defenses in normal and immunocompromised hosts as well as lung immunology in disease such as cystic fibrosis and asthma. Additional research interests of Dr. Kolls include gene therapy, lung immunology, lung host defenses, tumor necrosis factor, pneumocytis carinii pneumonia, ethanol, gene expression, polymerase chain reaction and molecular biology.
Children's Hospital of Pittsburgh
Results of the study are published in the February online issue of Nature Medicine.
"Currently there is no vaccine that covers all kinds of pneumonia and antibiotic treatment is sometimes limited by antibiotic resistance. As acute respiratory infections are the no. 1 killer of children in the world, progress in the development of novel vaccines or new, more effective treatments is critical," said Dr. Kolls, the Neils K. Jerne Professor of Pediatrics and Immunology at the University of Pittsburgh School of Medicine. "Our results raise the possibility of developing new protein-based therapies using IL-22 to limit or prevent pneumonia."
Pneumonia causes almost one in five deaths in children under age 5 worldwide - more than 2 million children each year, according to the World Health Organization. It kills more children than any other disease - more than AIDS and malaria combined.
IL-22 and interleukin 17A (IL-17A) are produced by a recently discovered lineage of cells known as T Helper Type 17 (Th17). Children's researchers found evidence that the Th17 cell lineage and its cytokines IL-22 and IL-17A have evolved to promote host defense against certain infections in the lung caused by extracellular pathogens.
This is an important discovery because the Children's research team proposes that by stimulating the Th17 arm of the immune system, they can more efficiently treat bacterial pneumonia. Furthermore, the researchers propose that Th17 is a less critical pathway for intracellular bacteria such as those that cause listeria and tuberculosis - thus raising the potential to target this pathway in diseases of chronic inflammation such as rheumatoid arthritis or inflammatory bowel disease without increasing susceptibility to these intracellaulr pathogens.
Dr. Kolls' laboratory investigates mechanisms of lung host defenses in normal and immunocompromised hosts as well as lung immunology in disease such as cystic fibrosis and asthma. Additional research interests of Dr. Kolls include gene therapy, lung immunology, lung host defenses, tumor necrosis factor, pneumocytis carinii pneumonia, ethanol, gene expression, polymerase chain reaction and molecular biology.
Children's Hospital of Pittsburgh
Pneumonia Current Events and Pneumonia News RSSAmid the flu epidemic, don't forget RSV in young children
Influenza, particularly H1N1, has understandably captured the attention of public health officials, the media and the public.
Prioritizing low-cost, simple health measures would save 2.5 million child lives a year
Almost a third of the children under age five who die each year could be saved if governments rebalance health spending to ensure low-cost, simple interventions such as safe water and hygiene, bed nets and basic maternal and newborn care, leading aid agency World Vision said today. Currently, 8.8 million children a year die before age five, most of preventable causes.
Fewer emergency patients seen within recommended time frame
One in four emergency department patients in 2006 waited longer to be evaluated by a clinician than recommended at triage, an increase from one in five in 1997.
Possible help in fight against muscle-wasting disease
A compound already used to treat pneumonia could become a new therapy for an inherited muscular wasting disease, according to researchers at the University of Oregon and the University of Rochester School of Medicine and Dentistry in New York.
Henry Ford Hospital study: A MRSA strain linked to high death rates
A strain of MRSA that causes bloodstream infections is five times more lethal than other strains and has shown to have some resistance to the potent antibiotic drug vancomycin used to treat MRSA, according to a Henry Ford Hospital study.
Commentary warns of unexpected consequences of proton pump inhibitor use in reflux disease
Despite being highly effective and beneficial for many patients, unexpected consequences are emerging in patients who are prescribed proton pump inhibitors (PPIs) for reflux diseases.
Scientists discover influenza's Achilles heel: Antioxidants
As the nation copes with a shortage of vaccines for H1N1 influenza, a team of Alabama researchers have raised hopes that they have found an Achilles' heel for all strains of the flu-antioxidants.
Lessons from flu seasons past
Pregnant women who catch the flu are at serious risk for flu-related complications, including death, and that risk far outweighs the risk of possible side effects from injectable vaccines containing killed virus, according to an extensive review of published research and data from previous flu seasons.
Older Patients with Dementia at Increased Risk for Flu Mortality
An epidemiological study on pneumonia and influenza (P&I) in adults age 65 and over reports that patients with dementia are diagnosed with flu less frequently, have shorter hospital stays, and have a fifty percent higher rate of death than those without dementia.
OMRF scientists discover promising new path for treating traumas
A discovery by scientists at the Oklahoma Medical Research Foundation could help save lives threatened by traumatic injuries like those sustained in car crashes or on the battlefield. The work also holds potential for treating severe infectious diseases and diabetes.
More Pneumonia Current Events and Pneumonia News Articles
![GIANTmicrobes: Pneumonia (Streptococcus Pneumonia) [Toy] [Toy]](http://ecx.images-amazon.com/images/I/21j0zGn83gL._SL160_.jpg) |
GIANTmicrobes: Pneumonia (Streptococcus Pneumonia) [Toy] [Toy] by Giant Microbes Pneumonia can take your breath away. |
 |
Diagnosis and Management of Pneumonia and Other Respiratory Infections by Alan Fein (Author), Ronald Grossman (Author) Treatment of community-acquired pneumonia and hospital-acquired pneumonia, when to hospitalize a patient, methods of identifying low-risk CAP patients, switch and step-down therapy, approach to nonresloving pneumonia, management of parapneumonic effusions, empyema, and chronic bronchitis are discussed. The various antimicrobial agents are reviewed in deatil with suggested treatment regimens. |
 |
Pneumonia by Whiskeytown In their brief, volatile tenure as a working band--which spawned just two proper albums, Faithless Street (1995) and Strangers Almanac (1997)--Whiskeytown never quite fulfilled their considerable promise. But prior to their ultimate split, the band made a record that was buried for nearly three years by industry snafus. Pneumonia was well worth the wait. The band's final lineup (singer and songwriter Ryan Adams, violinist Caitlin Cary, and guitarist Mike Daly) is augmented by special guests such as Tommy Stinson of the Replacements and James Iha of Smashing Pumpkins. Sure, Adams doesn't quite grasp what he's reaching for on the Latin-tinged "Paper Moon," and "Sit & Listen to the Rain" is about as exciting as its title suggests. But "Jacksonville Skyline," a hometown ode that's sweetly... |
 |
Community Acquired Pneumonia Guidelines Pocketcard : Infecti by International Guidelines Cntr The Community-Acquired Pneumonia GUIDELINES Pocketcard is endorsed by the Infectious Diseases Society of America (IDSA). This practical quick-reference tool contains screening, diagnostic, treatment algorithm, drug therapy, dosing information, patient monitoring and counseling points. |
 |
Rockin' Pneumonia And The Boogie Woogie Flu Johnny Rivers (Primary Contributor) |
 |
Community-Acquired Pneumonia: Strategies for Management by Antoni Torres (Editor), Rosario Menendez (Editor) Community-Acquired Pneumonia (CAP) refers to pneumonia acquired outside of hospitals or extended-care facilities, and is distinct from Nosocomial or hospital-acquired pneumonia, which is a separate disease entity. It is one of the most common respiratory infections and presents one of the major health problems today, with an incidence that ranges from eight to fifty cases per thousand individuals each year. Mortality is still very high and yet the risk factors are very well known. Many of these are related to antibiotic treatment; delay in administration, inadequacy of empiric antibiotics and lack of adherence to guidelines for treatment are all clearly associated with poor treatment outcomes.
Following a description of the epidemiology and microbial etiology of... |
 |
Preventing Flu and Pneumonia (Home Use) Part of the award winning public television series Healthy Body/Healthy Mind. Nearly everyone has heard of "flu season." It's a time of year when forms of the influenza virus are more likely to infect people. Flu and another lung disease, Pneumonia, can be debilitating and deadly. According to the American Lung Association, flu and pneumonia together are ranked as the 7th leading cause of death in the United States. But there are steps people can take to prepare and try to prevent these conditions. This program will outline the basics about flu and pneumonia and offer physician recommendations on the best ways to prevent these diseases. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Community-Acquired Pneumonia GUIDELINES Pocketcard: Infectious Diseases Society of America and American Thoracic Society (2008) by International Guidelines Center The Community-Acquired Pneumonia GUIDELINES Pocketcard provides all that is needed to make accurate clinical decisions at the point of care including: Key Points; CURB-65 Severity Scores for CAP; Pneumonia PORT Severity Index (PSI); Evaluation and Initial Management Algorithm; Criteria for Severe Community Acquired Pneumonia; Clinical Indications for more Extensive Diagnostic Testing; Initial Empirical Antibiotic Therapy for Suspected Bacterial CAP; Current Medication Tables with Brand and Generic Names; Detailed drug information - strengths, formulations, comments. |
 |
Sav-A-Caf Scours & Pneumonia Treatment, 6 Lbs by Milk Products Inc Dried Animal Serum, Dried Whey Protein Concentrate, Animal Fat (Preserved With Bha, Bht, Citric Acid & Ethoxyquin), Dried Bovine Colostrum, Dried Whey, Coconut Oil, Glycine, Dicalcium Phosphate, Corn Syrup Solids, Etc. |
 |
Drug Resistant Pneumonia Directed By: Information Television Network |
| © 2009 BrightSurf.com |